XML 52 R27.htm IDEA: XBRL DOCUMENT
v3.23.1

Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Restatement of Previously Issued Unaudited Condensed Financial Statements |
Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements | Annovis Bio, Inc. Balance Sheets
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of March 31, 2022
​ | ​ | (unaudited)
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current assets: |  | ​ |  |  | ​ |  |  | ​ |
Cash and cash equivalents | ​ | $ | 42,668,838 | ​ | $ | — | ​ | $ | 42,668,838
Prepaid expenses and other current assets | ​ |  | 627,902 | ​ |  | 800,840 | ​ |  | 1,428,742
Deferred clinical materials | ​ |  | — | ​ |  | — | ​ |  | —
Total current assets | ​ |  | 43,296,740 | ​ |  | 800,840 | ​ |  | 44,097,580
Total Assets | ​ | $ | 43,296,740 | ​ | $ | 800,840 | ​ | $ | 44,097,580
Liabilities and Stockholders’ Equity | ​ |  |  | ​ |  |  | ​ |  |
Current liabilities: | ​ |  |  | ​ |  |  | ​ |  |
Accounts payable | ​ | $ | 928,997 | ​ | $ | — | ​ | $ | 928,997
Accrued expenses | ​ |  | 327,435 | ​ |  | 140,690 | ​ |  | 468,125
Total current liabilities | ​ |  | 1,256,432 | ​ |  | 140,690 | ​ |  | 1,397,122
Total liabilities | ​ | $ | 1,256,432 | ​ | $ | 140,690 | ​ | $ | 1,397,122
Commitments and contingencies (Note 7) | ​ |  |  | ​ |  |  | ​ |  |
Stockholders’ equity: | ​ |  |  | ​ |  |  | ​ |  |
Preferred stock – $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | ​ |  | — | ​ |  | — | ​ |  | —
Common stock – $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | ​ |  | 816 | ​ |  | — | ​ |  | 816
Additional paid-in capital | ​ |  | 76,659,912 | ​ |  | — | ​ |  | 76,659,912
Accumulated deficit | ​ |  | (34,620,420) | ​ |  | 660,150 | ​ |  | (33,960,270)
Total stockholders’ equity | ​ |  | 42,040,308 | ​ |  | 660,150 | ​ |  | 42,700,458
Total liabilities and stockholders’ equity | ​ | $ | 43,296,740 | ​ | $ | 800,840 | ​ | $ | 44,097,580
​ ​ Annovis Bio, Inc. Statements of Operations (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2022
​ | ​ | As | ​ | Restatement | ​ | As
​ |  | Reported |  | Impacts |  | Restated
Operating expenses: |  | ​ |  |  | ​ |  |  | ​ |
Research and development | ​ | $ | 2,809,791 | ​ | $ | (660,150) | ​ | $ | 2,149,641
General and administrative | ​ |  | 3,104,071 | ​ |  | — | ​ |  | 3,104,071
Total operating expenses | ​ |  | 5,913,862 | ​ |  | (660,150) | ​ |  | 5,253,712
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  | (5,913,862) | ​ |  | 660,150 | ​ |  | (5,253,712)
Other income: | ​ |  |  | ​ |  |  | ​ |  |
Interest income | ​ |  | 19,649 | ​ |  | — | ​ |  | 19,649
Grant Income | ​ |  | — | ​ |  | — | ​ |  | —
Total other income | ​ |  | 19,649 | ​ |  | — | ​ |  | 19,649
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss before income taxes | ​ |  | (5,894,213) | ​ |  | 660,150 | ​ |  | (5,234,063)
Income tax expense (benefit) | ​ |  | — | ​ |  | — | ​ |  | —
Net loss | ​ | $ | (5,894,213) | ​ | $ | 660,150 | ​ | $ | (5,234,063)
Basic and diluted loss per common share | ​ | $ | (0.72) | ​ |  | — | ​ | $ | (0.64)
Weighted average number of common shares outstanding, basic and diluted | ​ |  | 8,157,445 | ​ |  | — | ​ |  | 8,157,445
​ ​ Annovis Bio, Inc. Statements of Cash Flows (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2022
​ | ​ | As | ​ | ​ | ​ | As
​ | ​ | Reported | ​ | Restatement Impacts | ​ | Restated
Cash flows from operating activities: |  | ​ |  |  |  |  | ​ |
Net loss | ​ | $ | (5,894,213) |  | 660,150 | ​ | $ | (5,234,063)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ |  |  |  |  | ​ |  |
Stock-based compensation expense | ​ | ​ | 3,434,944 |  | — | ​ | ​ | 3,434,944
Changes in operating assets and liabilities: | ​ |  |  |  |  | ​ |  |
Prepaid expenses and other current assets | ​ | ​ | (312,438) |  | (800,840) | ​ | ​ | (1,113,278)
Accounts payable | ​ | ​ | 240,923 |  | — | ​ | ​ | 240,923
Accrued expenses | ​ | ​ | (491,005) |  | 140,690 | ​ | ​ | (350,315)
Net cash used in operating activities | ​ | ​ | (3,021,789) |  | — | ​ | ​ | (3,021,789)
Cash flows from financing activities: | ​ |  |  |  |  | ​ |  |
Proceeds from exercise of stock options | ​ | ​ | 4,613 |  | — | ​ | ​ | 4,613
Net cash used in financing activities | ​ | ​ | 4,613 |  | — | ​ | ​ | 4,613
Net (decrease) increase in cash and cash equivalents | ​ | ​ | (3,017,176) |  | — | ​ | ​ | (3,017,176)
Cash and cash equivalents, beginning of period | ​ | ​ | 45,686,014 |  | — | ​ | ​ | 45,686,014
Cash and cash equivalents, end of period | ​ | $ | 42,668,838 |  | — | ​ | $ | 42,668,838
​ ​ Annovis Bio, Inc. Balance Sheets ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | As of June 30, 2022
​ | ​ | (unaudited)
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 35,974,251 |  | $ | — | ​ | $ | 35,974,251
Prepaid expenses and other current assets | ​ |  | 551,072 | ​ |  | 3,441,895 | ​ |  | 3,992,967
Deferred clinical materials | ​ |  | — | ​ |  | — | ​ |  | —
Total current assets | ​ |  | 36,525,323 | ​ |  | 3,441,895 | ​ |  | 39,967,218
Total Assets | ​ | $ | 36,525,323 | ​ | $ | 3,441,895 | ​ | $ | 39,967,218
Liabilities and Stockholders’ Equity | ​ |  |  | ​ |  |  | ​ |  |
Current liabilities: | ​ |  |  | ​ |  |  | ​ |  |
Accounts payable | ​ | $ | 901,841 | ​ | $ | — | ​ | $ | 901,841
Accrued expenses | ​ |  | 397,544 | ​ |  | — | ​ |  | 397,544
Total current liabilities | ​ |  | 1,299,385 | ​ |  | — | ​ |  | 1,299,385
Total liabilities | ​ | $ | 1,299,385 | ​ | $ | — | ​ | $ | 1,299,385
Commitments and contingencies (Note 7) | ​ |  |  | ​ |  |  | ​ |  |
Stockholders’ equity: | ​ |  |  | ​ |  |  | ​ |  |
Preferred stock – $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | ​ |  | — | ​ |  | — | ​ |  | —
Common stock – $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | ​ |  | 816 | ​ |  | — | ​ |  | 816
Additional paid-in capital | ​ |  | 78,563,673 | ​ |  | — | ​ |  | 78,563,673
Accumulated deficit | ​ |  | (43,338,551) | ​ |  | 3,441,895 | ​ |  | (39,896,656)
Total stockholders’ equity | ​ |  | 35,225,938 | ​ |  | 3,441,895 | ​ |  | 38,667,833
Total liabilities and stockholders’ equity | ​ | $ | 36,525,323 | ​ | $ | 3,441,895 | ​ | $ | 39,967,218
​ ​ Annovis Bio, Inc. Statements of Operations (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended June 30, 2022
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | $ | 6,815,708 | ​ | $ | (2,781,745) | ​ | $ | 4,033,963
General and administrative | ​ |  | 1,938,447 | ​ |  | – | ​ |  | 1,938,447
Total operating expenses | ​ |  | 8,754,155 | ​ |  | (2,781,745) | ​ |  | 5,972,410
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  | (8,754,155) | ​ |  | 2,781,745 | ​ |  | (5,972,410)
Other income: | ​ |  |  | ​ |  |  | ​ |  |
Interest income | ​ |  | 36,024 | ​ |  | — | ​ |  | 36,024
Grant Income | ​ |  | — | ​ |  | — | ​ |  | —
Total other income | ​ |  | 36,024 | ​ |  | — | ​ |  | 36,024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss before income taxes | ​ |  | (8,718,131) | ​ |  | 2,781,745 | ​ |  | (5,936,386)
Income tax expense (benefit) | ​ |  | — | ​ |  | — | ​ |  | —
Net loss | ​ | $ | (8,718,131) | ​ | $ | 2,781,745 | ​ | $ | (5,936,386)
Basic and diluted loss per common share | ​ | $ | (1.07) | ​ |  | — | ​ | $ | (0.73)
Weighted average number of common shares outstanding, basic and diluted | ​ |  | 8,163,923 | ​ |  | — | ​ |  | 8,163,923
​ ​ Annovis Bio, Inc. Statements of Operations (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended June 30, 2022
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | $ | 9,625,499 | ​ | $ | (3,441,895) | ​ | $ | 6,183,604
General and administrative | ​ |  | 5,042,518 | ​ |  | — | ​ |  | 5,042,518
Total operating expenses | ​ |  | 14,668,017 | ​ |  | (3,441,895) | ​ |  | 11,226,122
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  | (14,668,017) | ​ |  | 3,441,895 | ​ |  | (11,226,122)
Other income: | ​ |  |  | ​ |  |  | ​ |  |
Interest income | ​ |  | 55,673 | ​ |  | — | ​ |  | 55,673
Grant Income | ​ |  | — | ​ |  | — | ​ |  | —
Total other income | ​ |  | 55,673 | ​ |  | — | ​ |  | 55,673
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss before income taxes | ​ |  | (14,612,344) | ​ |  | 3,441,895 | ​ |  | (11,170,449)
Income tax expense (benefit) | ​ |  | — | ​ |  | — | ​ |  | —
Net loss | ​ | $ | (14,612,344) | ​ | $ | 3,441,895 | ​ | $ | (11,170,449)
Basic and diluted loss per common share | ​ | $ | (1.79) | ​ |  | — | ​ | $ | (1.37)
Weighted average number of common shares outstanding, basic and diluted | ​ |  | 8,160,702 | ​ |  | — | ​ |  | 8,160,702
​ ​ Annovis Bio, Inc. Statements of Cash Flows (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended June 30, 2022
​ | ​ | As | ​ | ​ | ​ | ​ | As
​ | ​ | Reported | ​ | Restatement Impacts | ​ | Restated
Cash flows from operating activities: |  | ​ |  |  | ​ |  |  | ​ |
Net loss | ​ | $ | (14,612,344) |  | ​ | 3,441,895 | ​ | $ | (11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ |  |  |  | ​ |  | ​ |  |
Stock-based compensation expense | ​ | ​ | 5,338,705 |  | ​ | — | ​ | ​ | 5,338,705
Changes in operating assets and liabilities: | ​ |  |  |  | ​ |  | ​ |  |
Prepaid expenses and other current assets | ​ | ​ | (235,608) |  | ​ | (3,441,895) | ​ | ​ | (3,677,503)
Accounts payable | ​ | ​ | 213,767 | ​ | $ | 213,767 | ​ |  |
Accrued expenses | ​ | ​ | (420,896) | ​ | $ | (420,896) | ​ |  |
Net cash used in operating activities | ​ | ​ | (9,716,376) | ​ |  | — | ​ | ​ | (9,716,376)
Cash flows from financing activities: | ​ |  |  | ​ |  |  | ​ |  |
Proceeds from issuance of common stock, net of issuance costs | ​ | ​ | — | ​ |  | — | ​ | ​ | —
Proceeds from exercise of stock options | ​ | ​ | 4,613 | ​ |  | — | ​ | ​ | 4,613
Net cash used in financing activities | ​ | ​ | 4,613 | ​ |  | — | ​ | ​ | 4,613
Net (decrease) increase in cash and cash equivalents | ​ | ​ | (9,711,763) | ​ |  | — | ​ | ​ | (9,711,763)
Cash and cash equivalents, beginning of period | ​ | ​ | 45,686,014 | ​ |  | — | ​ | ​ | 45,686,014
Cash and cash equivalents, end of period | ​ | $ | 35,974,251 | ​ |  | — | ​ | $ | 35,974,251
​ ​ Annovis Bio, Inc. Balance Sheets ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of September 30, 2022
​ | ​ | (unaudited)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As | ​ | Restatement | ​ | As
​ |  | Reported |  | Impacts |  | Restated
Assets |  | ​ |  |  | ​ |  |  | ​ |
Current assets: |  | ​ |  |  | ​ |  |  | ​ |
Cash and cash equivalents | ​ | $ | 31,987,091 | ​ | $ | — | ​ | $ | 31,987,091
Prepaid expenses and other current assets | ​ |  | 499,947 | ​ |  | 4,631,390 | ​ |  | 5,131,337
Total current assets | ​ |  | 32,487,038 | ​ |  | 4,631,390 | ​ |  | 37,118,428
Total Assets | ​ | $ | 32,487,038 | ​ | $ | 4,631,390 | ​ | $ | 37,118,428
Liabilities and Stockholders’ Equity | ​ |  |  | ​ |  |  | ​ |  |
Current liabilities: | ​ |  |  | ​ |  |  | ​ |  |
Accounts payable | ​ | $ | 1,845,705 | ​ | $ | — | ​ | $ | 1,845,705
Accrued expenses | ​ |  | 680,830 | ​ |  | — | ​ |  | 680,830
Total current liabilities | ​ |  | 2,526,535 | ​ |  | — | ​ |  | 2,526,535
Total liabilities | ​ | $ | 2,526,535 | ​ | $ | — | ​ | $ | 2,526,535
Commitments and contingencies (Note 7) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders’ equity: | ​ |  |  | ​ |  |  | ​ |  |
Preferred stock – $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | ​ |  | — | ​ |  | — | ​ |  | —
Common stock – $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | ​ |  | 816 | ​ |  | — | ​ |  | 816
Additional paid-in capital | ​ |  | 80,919,684 | ​ |  | — | ​ |  | 80,919,684
Accumulated deficit | ​ |  | (50,959,997) | ​ |  | 4,631,390 | ​ |  | (46,328,607)
Total stockholders’ equity | ​ |  | 29,960,503 | ​ |  | 4,631,390 | ​ |  | 34,591,893
Total liabilities and stockholders’ equity | ​ | $ | 32,487,038 | ​ | $ | 4,631,390 | ​ | $ | 37,118,428
​ ​ Annovis Bio, Inc. Statements of Operations (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, 2022
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | $ | 5,313,033 | ​ | $ | (1,189,495) | ​ | $ | 4,123,538
General and administrative | ​ |  | 2,361,299 | ​ |  | — | ​ |  | 2,361,299
Total operating expenses | ​ |  | 7,674,332 | ​ |  | (1,189,495) | ​ |  | 6,484,837
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  | (7,674,332) | ​ |  | 1,189,495 | ​ |  | (6,484,837)
Other income: | ​ |  |  | ​ |  |  | ​ |  |
Interest income | ​ |  | 52,886 | ​ |  | — | ​ |  | 52,886
Grant Income | ​ |  | — | ​ |  | — | ​ |  | —
Total other income | ​ |  | 52,886 | ​ |  | — | ​ |  | 52,886
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss before income taxes | ​ |  | (7,621,446) | ​ |  | 1,189,495 | ​ |  | (6,431,951)
Income tax expense (benefit) | ​ |  | — | ​ |  | — | ​ |  | —
Net loss | ​ | $ | (7,621,446) | ​ | $ | 1,189,495 | ​ | $ | (6,431,951)
Basic and diluted loss per common share | ​ | $ | (0.93) | ​ |  | — | ​ | $ | (0.79)
Weighted average number of common shares outstanding, basic and diluted | ​ |  | 8,163,923 | ​ |  | — | ​ |  | 8,163,923
​ ​ Annovis Bio, Inc. Statements of Operations (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended September 30, 2022
​ |  | As |  | Restatement |  | As
​ | ​ | Reported | ​ | Impacts | ​ | Restated
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | $ | 14,938,532 | ​ | $ | (4,631,390) | ​ | $ | 10,307,142
General and administrative | ​ |  | 7,403,817 | ​ |  | – | ​ |  | 7,403,817
Total operating expenses | ​ |  | 22,342,349 | ​ |  | (4,631,390) | ​ |  | 17,710,959
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  | (22,342,349) | ​ |  | 4,631,390 | ​ |  | (17,710,959)
Other income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest income | ​ |  | 108,559 | ​ |  | — | ​ |  | 108,559
Grant Income | ​ |  | — | ​ | ​ | — | ​ |  | –
Total other income | ​ |  | 108,559 | ​ |  | — | ​ |  | 108,559
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss before income taxes | ​ |  | (22,233,790) | ​ |  | 4,631,390 | ​ |  | (17,602,400)
Income tax expense (benefit) | ​ |  | — | ​ |  | — | ​ |  | —
Net loss | ​ | $ | (22,233,790) | ​ | $ | 4,631,390 | ​ | $ | (17,602,400)
Basic and diluted loss per common share | ​ | $ | (2.72) | ​ |  | — | ​ | $ | (2.16)
Weighted average number of common shares outstanding, basic and diluted | ​ |  | 8,161,787 | ​ |  | — | ​ |  | 8,161,787
​ ​ Annovis Bio, Inc. Statements of Cash Flows (unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended September 30, 2022
​ | ​ | As | ​ | ​ | ​ | As
​ | ​ | Reported | ​ | Restatement Impacts | ​ | Restated
Cash flows from operating activities: |  | ​ |  |  |  |  | ​ |
Net loss | ​ | $ | (22,233,790) |  | 4,631,390 | ​ | $ | (17,602,400)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ |  |  |  |  | ​ |  |
Stock-based compensation expense | ​ | ​ | 7,694,716 |  | — | ​ | ​ | 7,694,716
Changes in operating assets and liabilities: | ​ |  |  |  |  | ​ |  |
Prepaid expenses and other current assets | ​ | ​ | (184,483) |  | (4,631,390) | ​ | ​ | (4,815,873)
Accounts payable | ​ | ​ | 1,157,631 |  | — | ​ | ​ | 1,157,631
Accrued expenses | ​ | ​ | (137,610) |  | — | ​ | ​ | (137,610)
Net cash used in operating activities | ​ | ​ | (13,703,536) |  | — | ​ | ​ | (13,703,536)
Cash flows from financing activities: | ​ |  |  |  |  | ​ |  |
Proceeds from issuance of common stock, net of issuance costs | ​ | ​ | — |  | — | ​ | ​ | —
Proceeds from exercise of stock options | ​ | ​ | 4,613 |  | — | ​ | ​ | 4,613
Net cash used in financing activities | ​ | ​ | 4,613 |  | — | ​ | ​ | 4,613
Net (decrease) increase in cash and cash equivalents | ​ | ​ | (13,698,923) |  | — | ​ | ​ | (13,698,923)
Cash and cash equivalents, beginning of period | ​ | ​ | 45,686,014 |  | — | ​ | ​ | 45,686,014
Cash and cash equivalents, end of period | ​ | $ | 31,987,091 |  | — | ​ | $ | 31,987,091

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialDataAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration